Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer. | D Prestwich et al. Radiation Oncology 2010 5 121 http content 5 1 121 RADIATION ONCOLOGY RESEARCH Open Access A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer Robin J D Prestwich Kiran Kancherla Didem Colpan Oksuz Deborah Williamson Karen E Dyker Catherine Coyle Mehmet Sen Abstract Background Chemo-radiotherapy offers an alternative to primary surgery and adjuvant therapy for the management of locally advanced stage IV squamous cell carcinomas of the tonsil. Methods A retrospective analysis was performed of the outcomes of 41 patients with locoregionally advanced squamous cell carcinoma of the tonsil treated non-surgically at the Yorkshire Cancer Centre between January 2004 and December 2005. Due to long radiotherapy waiting times patients received induction chemotherapy with cisplatin and 5-fluorouracil followed by either cisplatin concurrent chemoradiotherapy or radiotherapy alone. Results Median age was 55 years range 34-76 years and 28 68 patients were male. 35 41 patients 85 received 2 or more cycles of induction chemotherapy. Following induction chemotherapy 32 41 patients 78 had a clinical response. Concomitant chemotherapy was given to 30 41 73 . All patients received the planned radiotherapy dose with no delays. There were no treatment related deaths. Six 15 patients had gastrostomy tubes placed before treatment and 22 54 required nasogastric tube placement during or after treatment for nutritional support. 17 patients required unplanned admissions during treatment for supportive care. At 4 months post treatment assessment 35 out of 41 85 patients achieved complete clinical and radiographic response. Median follow-up is 38 months 8-61 months . Local and regional control rate in complete responders at 3 years was 91 . Distant metastases have been found in 4 patients. Three year progression-free survival rate in all patients is 75 . The 3-year cause specific .
